Financial Performance - The company's operating revenue for Q1 2023 was ¥120,153,487.21, representing a 3.21% increase compared to ¥116,414,221.46 in the same period last year[4] - Net profit attributable to shareholders was ¥17,223,917.74, reflecting a 10.72% increase from ¥15,555,857.99 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥16,603,160.43, which is a 25.64% increase from ¥13,215,162.48 in the previous year[4] - The total operating revenue for Q1 2023 was CNY 120,153,487.21, an increase from CNY 116,414,221.46 in the previous period, representing a growth of approximately 2.5%[15] - The net profit for Q1 2023 was CNY 17,522,185.87, an increase of 13.3% compared to CNY 15,488,115.00 in Q1 2022[16] - Operating profit for the quarter reached CNY 19,705,509.83, up from CNY 17,153,491.13, reflecting a growth of 14.9% year-over-year[16] - Total comprehensive income for Q1 2023 was CNY 19,325,035.87, significantly higher than CNY 5,443,665.00 in the same period last year[16] - Basic earnings per share for Q1 2023 were CNY 0.10, up from CNY 0.09 in Q1 2022, reflecting a growth of 11.1%[16] Cash Flow and Assets - The company's cash flow from operating activities decreased by 16.37% to ¥16,636,610.36, down from ¥19,892,602.11 in the same quarter last year[4] - Cash flow from operating activities generated a net amount of CNY 16,636,610.36, down from CNY 19,892,602.11 in Q1 2022, indicating a decrease of 11.3%[18] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 512,266,644.24, compared to CNY 474,457,318.97 at the end of Q1 2022, showing an increase of 8.0%[19] - The net increase in cash and cash equivalents was -¥17,530,104.83, a decrease of 121.08% compared to an increase of ¥83,168,102.30 in the previous year[8] - Cash and cash equivalents at the end of the period were CNY 548,102,286.98, slightly up from CNY 538,553,452.28 at the beginning of the year[12] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,149,867,938.58, a decrease of 0.71% from ¥2,165,349,466.00 at the end of the previous year[4] - The total assets as of March 31, 2023, were CNY 2,149,867,938.58, down from CNY 2,165,349,466.00 at the beginning of the year[14] - The total liabilities decreased to CNY 179,096,919.64 from CNY 213,903,482.93, showing a decline of about 16.3%[14] - The total equity attributable to shareholders increased to CNY 1,965,601,858.99 from CNY 1,946,575,091.25, reflecting a growth of approximately 1.0%[14] Expenses and Investments - The total operating costs decreased to CNY 106,830,552.14 from CNY 109,850,025.97, reflecting a reduction of about 2.8%[15] - Research and development expenses increased to CNY 6,559,933.54, up from CNY 5,184,920.83, indicating a rise of approximately 26.5%[15] - The company reported a decrease in cash inflow from investment activities, with a net cash flow of -CNY 2,828,433.91 compared to CNY 62,553,193.26 in the previous year[19] - The company reported a net investment income of CNY 4,051,036.65, down from CNY 5,974,979.15, representing a decrease of approximately 32.2%[15] - The company experienced a significant increase in financial expenses, amounting to -¥970,017.78, primarily due to increased interest income[7] - The company experienced a significant increase in credit impairment losses, amounting to CNY 1,380,454.52, compared to CNY 2,828,371.43 in the previous year[16] Receivables and Inventory - Accounts receivable decreased by 32.56% to ¥84,951,418.77, down from ¥125,956,911.98 in the previous year[7] - The accounts receivable decreased to CNY 84,951,418.77 from CNY 125,956,911.98, a reduction of approximately 32.5%[12] - The inventory level decreased to CNY 99,947,943.11 from CNY 105,968,149.33, indicating a decline of about 5.7%[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,235[9] - The company reported a tax expense of CNY 2,133,700.40 for the quarter, compared to CNY 1,280,012.86 in the same period last year, indicating an increase of 66.7%[16]

宏达高科控股股份有限公司 Hongda High-Tech Holding Co.,Ltd. （002144） 2022 年年度报告 2023 年 4 月 宏达高科控股股份有限公司2022年年度报告全文 第一节 重要提示、目录和释义 ...

编号：2015-006 证券代码：002144 证券简称：宏达高科 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------------------| | | | | | 投资者关系 | □ | 特定对象调研 □分析师会议 | | 活动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | | □ | 现场参观 □现场调研 | | | ■ 其他 : | 投资者接待日（请文字说明其他活动内容） | | 参与单位名 | | 上海湘禾投资：陈永胜；上海新源变频电器：张晓钟；上海璞盈投 | | 称及人员姓 | | 资：张岑岭；梵蒂冈投资管理：毛伟；个人投资者：袁建平、姜向 | | 名 | 勤良。 | 花、李勇、宋荣强、何昌华、江荣生、赵洛青、邵荣池、王嘉、项影康、黄 | | 时间 | 2015 年 5 月 15 | 日上午 10 点 | | 地点 | 浙江省海宁市许村镇建设路 | 1 ...

编号：2014-015 证券代码：002144 证券简称：宏达高科 宏达高科控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------|---------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | | □ 现场参观 ■现场调研 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 爱建证券：侯佳林，刘孙亮；上海璞盈投资：张岑岭 | | 时间 | 2014 年 11 月 18 | 日下午二点 | | 地点 | 浙江省海宁市许村镇建设路 | 118 号公司会议室 | | 上市公司接待 人员姓名 | | 董事会秘书朱海东、证券部科员马强强 ...

编号：2014-014 证券代码：002144 证券简称：宏达高科 宏达高科控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|----------------------------|-------------------------------------------------------------------------| | | | | | 投资者关系活 | □ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | | □ 现场参观 ■现场调研 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称 | | 华泰证券：姚宏光，谢志才，银华基金：和玮，财通证券：沈 | | 及人员姓名 | | 吉，戴中伟，沈剑华，招商基金：周洪伟 | | 时间 | 2014 年 11 月 7 | 日上午九点半 | | 地点 上市公司接待 | 浙江省海宁市许村镇建设路 | 118 号公司会议室 董事会秘书朱海东、证券事务代表汪婵、 ...

编号：2015-001 证券代码：002144 证券简称：宏达高科 宏达高科控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------|------------------------------------------------------------| | | | | | 投资者关系活 | □ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | | □ 现场参观 ■现场调研 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 海通证券：唐苓，天津海达创投：阚浩 | | 时间 | 2015 年 1 月 19 | 日下午三点 | | 地点 | 浙江省海宁市许村镇建设路 | 118 号公司会议室 | | 上市公司接待 人员姓名 | | 董事会秘书朱海东、证券事务代表汪婵、证券部科员马强强 | | 投资者关系活 | | 问题一：请问公司在体外诊断试剂的进展 ...